acetasvir (DCV) is a potent antiviral agent used for the treatment of hepatitis C virus (HCV) infection. However, its poor aqueous solubility and low bioavailability pose challenges in achieving optimal therapeutic efficacy. In this study, we aimed to develop and evaluate a nanosuspension formulation of DCV to improve its solubility, dissolution rate, and bioavailability.The nanosuspension formulation was prepared using a top-down approach, employing a high-pressure homogenization technique. A combination of hydrophilic and hydrophobic stabilizers was incorporated to enhance the physical stability and prevent particle aggregation. The particle size, polydispersity index, zeta potential, and morphology of the nanosuspension were characterized using dynamic light scattering and transmission electron microscopy.In conclusion, the developed DCV nanosuspension showed promising results in terms of particle size reduction, enhanced dissolution rate, and improved bioavailability and stability. The optimized formulation (F6) shered particle size of PDI 0.32 And Drug release 96.54% contrast pure drug formulation which has 99.45% This nanosuspension formulation holds great potential for overcoming the solubility and bioavailability challenges associated with DCV, ultimately leading to improved therapeutic outcomes for patients with HCV infection.